Suppliers and packagers for NEBIVOLOL HYDROCHLORIDE

NEBIVOLOL HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ani Pharms	NEBIVOLOL HYDROCHLORIDE	nebivolol hydrochloride	TABLET;ORAL	203659	ANDA	Golden State Medical Supply, Inc.	51407-483-30	30 TABLET in 1 BOTTLE (51407-483-30)	2015-04-16
Ani Pharms	NEBIVOLOL HYDROCHLORIDE	nebivolol hydrochloride	TABLET;ORAL	203659	ANDA	Golden State Medical Supply, Inc.	51407-484-30	30 TABLET in 1 BOTTLE (51407-484-30)	2015-04-16
Ani Pharms	NEBIVOLOL HYDROCHLORIDE	nebivolol hydrochloride	TABLET;ORAL	203659	ANDA	Golden State Medical Supply, Inc.	51407-484-90	90 TABLET in 1 BOTTLE (51407-484-90)	2015-04-16

NEBIVOLOL HYDROCHLORIDE API SUPPLIERS: SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report identifies key suppliers for Nebivolol Hydrochloride Active Pharmaceutical Ingredient (API), examining their regulatory status, manufacturing capabilities, and recent market activities. The analysis focuses on entities with demonstrated production capacity and a history of supplying to regulated markets.

GLOBAL API SUPPLIERS FOR NEBIVOLOL HYDROCHLORIDE

The market for Nebivolol Hydrochloride API is served by a limited number of manufacturers, primarily concentrated in India and China, with some presence in Europe. These suppliers are crucial for the production of generic Nebivolol Hydrochloride products used in treating hypertension.

Primary Manufacturing Locations

• India: A significant hub for API manufacturing, Indian companies possess established facilities and regulatory expertise.
• China: China is a major global supplier of APIs, with a substantial capacity for complex pharmaceutical ingredients.
• Europe: While less dominant in volume, European manufacturers often focus on specialized or high-quality APIs and maintain stringent regulatory compliance.

Key Suppliers and Their Regulatory Standing

The following entities have been identified as significant suppliers or potential suppliers of Nebivolol Hydrochloride API. Regulatory compliance, indicated by certifications such as US Food and Drug Administration (US FDA) inspections and European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificates of Suitability (CEPs), is critical for market access in major pharmaceutical markets.

• Laurus Labs Limited (India):

  • Regulatory Status: Holds US FDA-approved facilities and EDQM CEPs for various APIs. Lacks specific public documentation confirming a Nebivolol HCl CEP, but its broad API portfolio suggests capability.
  • Manufacturing Capacity: Operates large-scale, multi-product facilities.
  • Market Presence: A major exporter of APIs to regulated markets.

• Divi’s Laboratories Limited (India):

  • Regulatory Status: Consistently undergoes US FDA inspections with successful outcomes. Holds numerous EDQM CEPs. Specific CEP for Nebivolol HCl is publicly unavailable but its extensive API catalog is relevant.
  • Manufacturing Capacity: Known for significant capacity in complex chemistry and dedicated manufacturing blocks.
  • Market Presence: A leading global API supplier with a strong track record.

• Granules India Limited (India):

  • Regulatory Status: US FDA and EDQM compliant facilities. Granules India is known for its portfolio of cardiovascular APIs. Public records for a Nebivolol HCl CEP are not immediately available.
  • Manufacturing Capacity: Operates integrated manufacturing sites.
  • Market Presence: Supplies to numerous regulated markets.

• Hikma Pharmaceuticals PLC (Portugal/Jordan):

  • Regulatory Status: Hikma’s API division, Hikma Generics, operates in compliance with US FDA and European regulatory standards. Specific API focus and Nebivolol HCl CEP status require direct inquiry.
  • Manufacturing Capacity: Possesses substantial API manufacturing capabilities across its global sites.
  • Market Presence: A significant player in generic pharmaceuticals and API supply.

• Aarti Drugs Limited (India):

  • Regulatory Status: Aarti Drugs has a history of US FDA and EDQM audits. While they produce a wide range of APIs, a specific CEP for Nebivolol HCl is not prominently listed.
  • Manufacturing Capacity: Possesses established chemical synthesis capabilities.
  • Market Presence: Supplies to domestic and international markets.

• Ruskon (China):

  • Regulatory Status: Chinese API manufacturers often supply to less regulated markets or act as contract manufacturers. US FDA inspections and EDQM CEPs for specific products vary and require due diligence.
  • Manufacturing Capacity: China has a vast API manufacturing infrastructure.
  • Market Presence: A significant source for global API supply chains.

• Zhejiang NHU Company Ltd. (China):

  • Regulatory Status: NHU is a large chemical and pharmaceutical group with facilities subject to international quality standards. Specific Nebivolol HCl regulatory filings need confirmation.
  • Manufacturing Capacity: Substantial chemical synthesis and API production capabilities.
  • Market Presence: A major producer of various pharmaceutical intermediates and APIs.

REGULATORY LANDSCAPE AND COMPLIANCE

Access to key pharmaceutical markets, particularly the United States and Europe, necessitates adherence to stringent regulatory requirements. For Nebivolol Hydrochloride API suppliers, this translates to:

• US FDA Inspections: Facilities must undergo and pass US FDA inspections to supply to the U.S. market. The US FDA maintains a public database of inspection observations and actions.
• EDQM Certificates of Suitability (CEPs): A CEP demonstrates that the quality of a substance is suitably controlled by the relevant monograph(s) of the European Pharmacopoeia. It simplifies the regulatory process for drug product manufacturers seeking marketing authorization in Europe and other regions that recognize CEPs.
• Good Manufacturing Practices (GMP): All suppliers must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies. This includes robust quality management systems, process validation, and detailed documentation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities (e.g., US FDA, Health Canada). These confidential documents provide detailed information about the manufacturing process, facilities, and controls of the API. Drug product manufacturers can then reference these DMFs in their marketing applications.

SUPPLY CHAIN CONSIDERATIONS

The selection of a Nebivolol Hydrochloride API supplier involves evaluating several critical factors beyond regulatory compliance.

Quality and Consistency

• Purity Profile: The API must meet strict purity specifications to ensure the safety and efficacy of the final drug product. Impurities can arise from the synthesis process or degradation and must be identified, quantified, and controlled.
• Batch-to-Batch Consistency: Consistent quality across all manufacturing batches is paramount. This is achieved through validated manufacturing processes and rigorous in-process and final product testing.
• Stability Studies: Comprehensive stability data is required to confirm the API's shelf-life under defined storage conditions.

Manufacturing Capability and Scale

• Production Volume: Suppliers must demonstrate the capacity to meet projected demand for Nebivolol Hydrochloride. This includes understanding their current output and their ability to scale up production if necessary.
• Process Robustness: The manufacturing process must be robust and reproducible, capable of consistently producing API that meets specifications.
• Technological Expertise: Nebivolol Hydrochloride synthesis involves multi-step chemical reactions. Suppliers with proven expertise in complex organic synthesis are preferred.

Cost and Commercial Terms

• Pricing: API pricing is a significant factor, influenced by raw material costs, manufacturing efficiency, and market competition.
• Supply Agreements: Formal supply agreements define pricing, delivery schedules, quality standards, and intellectual property considerations.
• Lead Times: Predictable and manageable lead times are essential for inventory planning and avoiding drug shortages.

Risk Mitigation

• Supply Chain Diversification: Relying on a single supplier can introduce significant risk. Identifying and qualifying multiple suppliers is a strategy for supply chain resilience.
• Geopolitical and Environmental Factors: Assess potential disruptions from geopolitical instability, natural disasters, or stringent environmental regulations impacting manufacturing locations.
• Intellectual Property (IP): While Nebivolol Hydrochloride itself is off-patent, understanding the IP landscape related to specific manufacturing processes or polymorphs is crucial.

RECENT MARKET DEVELOPMENTS

The Nebivolol Hydrochloride market is largely driven by generic competition. Manufacturers focus on cost-effective production while maintaining high quality to capture market share.

• Generic Drug Approvals: Regulatory bodies like the US FDA and European Medicines Agency (EMA) continuously approve new generic Nebivolol Hydrochloride drug products. Each approval creates demand for API from qualifying suppliers.
• Price Pressure: Increased competition among generic manufacturers and API suppliers leads to downward pressure on pricing.
• Focus on Indian and Chinese Suppliers: These regions continue to dominate API supply due to cost advantages and established manufacturing infrastructure. However, increased scrutiny on quality and regulatory compliance from Western authorities is a constant factor.

KEY TAKEAWAYS

• Nebivolol Hydrochloride API supply is primarily concentrated among manufacturers in India and China, with European players also present.
• Regulatory compliance, specifically US FDA inspections and EDQM CEPs, is a critical differentiator for suppliers targeting regulated markets.
• Key suppliers like Laurus Labs, Divi’s Laboratories, and Granules India have established reputations for quality and regulatory adherence, though specific Nebivolol HCl CEPs require direct confirmation.
• Supply chain diversification and thorough due diligence regarding manufacturing capabilities, quality control, and cost are essential for pharmaceutical companies sourcing this API.
• The market is characterized by ongoing generic competition, driving price efficiency alongside stringent quality demands.

FAQS

What are the main regulatory hurdles for Nebivolol Hydrochloride API suppliers?

The primary regulatory hurdles include obtaining and maintaining US FDA approval for manufacturing facilities and securing EDQM Certificates of Suitability (CEPs) for the European market. Adherence to current Good Manufacturing Practices (cGMP) and submission of comprehensive Drug Master Files (DMFs) are also mandatory.

How does the patent status of Nebivolol affect API suppliers?

Nebivolol's primary patents have expired in most major markets, enabling generic drug development. This has intensified competition among API manufacturers, driving a focus on cost-effective production while maintaining high quality to secure supply contracts for generic formulations.

What are the typical lead times for Nebivolol Hydrochloride API orders?

Typical lead times for bulk API orders can range from 8 to 16 weeks, depending on the supplier's production schedule, existing backorders, and the complexity of the synthesis. Rush orders may be accommodated with premium pricing or at the supplier's discretion.

How can a pharmaceutical company assess the quality and consistency of an API supplier?

Assessment involves reviewing the supplier's regulatory filings (US FDA inspection reports, CEPs), conducting on-site audits of manufacturing facilities, requesting detailed Certificates of Analysis (CoAs) for multiple batches, and evaluating their quality management system. Stability data and impurity profiling are also critical components of quality assessment.

What are the risks associated with a highly consolidated API supply market for Nebivolol Hydrochloride?

A consolidated market presents risks such as limited negotiation power for buyers, potential supply chain disruptions if a major supplier faces production issues or regulatory action, and reduced innovation due to lower competitive intensity. Diversifying the supplier base is a key strategy to mitigate these risks.

Cited Sources

1. Company Websites (Laurus Labs Limited, Divi’s Laboratories Limited, Granules India Limited, Hikma Pharmaceuticals PLC, Aarti Drugs Limited, Zhejiang NHU Company Ltd.). Accessed November 2023.
2. European Directorate for the Quality of Medicines & HealthCare (EDQM). Certificate of Suitability Database. [Specific query results for Nebivolol Hydrochloride are proprietary and require direct access or inquiry.]
3. U.S. Food and Drug Administration (US FDA). Establishment Registration & Drug Listing. [Publicly accessible databases for facility inspections and approved DMFs.]
4. Pharmaceutical Market Research Reports (e.g., Global Nebivolol Hydrochloride Market Analysis). [Specific report titles and publishers vary and are proprietary market intelligence.]